Supplemental Table S4. Comparison of the Incidence of Rebound Hyperglycemia by Group: Delayed Basal Insulin Group Was Set as Patients Starting Basal Insulin before Discontinuation of Continuous Intravenous Insulin Infusion

Variable	Odds ratio (95% CI)	P value
Univariable		
Group[a]	0.24 (0.10–0.58)	<0.001[b]
Multivariable		
Group[a]	0.23 (0.08–0.67)	0.007[b]
Age	0.99 (0.96–1.02)	0.447
Body mass index, kg/m^2	1.11 (0.98–1.27)	0.104
Classification (DKA)[c]	0.95 (0.20–4.48)	0.948
Classification (HHS)[c]	1.63 (0.34–7.76)	0.561
Classification (DKA with ketoacidosis)[c]	0.82 (0.20–3.26)	0.771
Dose of basal insulin, U	1.09 (0.96–1.24)	0.199
Duration of CIII, hr	0.98 (0.96–1.00)	0.039[b]
Glucose level immediately before CIII discontinuation, mg/dL	1.02 (1.00–1.03)	0.014[b]
Duration of DM, yr	1.00 (0.94–1.06)	0.967
Precipitating factor	2.01 (0.66–6.11)	0.228
OHA (metformin)	1.96 (0.49–7.87)	0.340
OHA (sulfonylurea)	1.02 (0.27–3.88)	0.976
OHA (DPP4 inhibitor)	0.30 (0.07–1.28)	0.103
OHA (SGLT2 inhibitor)	0.99 (0.13–7.50)	0.993

CI, confidence interval; DKA, diabetic ketoacidosis; HHS, hyperosmolar hyperglycemic state; CIII, continuous intravenous insulin infusion; DM, diabetes mellitus; OHA, oral hypoglycemic agent; DPP4, dipeptidyl peptidase 4; SGLT2, sodium/glucose cotransporter 2.
[a]Early vs. delayed basal insulin group; [b]Values are statistically significant ($P<0.05$) by logistic regression analyses; [c]Data are compared to the category of severe hyperglycemia that did not satisfy the criteria for either DKA or HHS.